Market Summary: The tetanus toxoid vaccine market reached a size of USD 1.43 billion in 2022, and it is projected to attain USD 2.42 billion by 2032, with a compound annual growth rate (CAGR) of 6% during the forecast period. Tetanus, caused by Clostridium tetani, is a bacterial infection resulting in neurological damage, muscle stiffness, and spasms, posing fatal risks. Immunization is the primary preventive measure against tetanus, leading to an increased demand for tetanus toxoid vaccines as public awareness of the importance of immunization against infectious diseases grows.
Government initiatives globally, such as the Expanded Program on Immunization by the World Health Organization (WHO), contribute to improved access to immunization in underdeveloped countries, fostering market revenue growth. The rise in tetanus cases worldwide, with an estimated 30,000 cases in 2020 according to the WHO, is a driving factor for increased demand for tetanus toxoid vaccines. Combination vaccinations, such as Diphtheria, Tetanus, and Pertussis (DTaP) and Tetanus, Diphtheria, and Pertussis (Tdap), offering protection against multiple diseases, further propel market revenue growth.
Get a sample copy of the Tetanus Toxoid Vaccine Market report: https://www.reportsanddata.com/report-detail/tetanus-toxoid-vaccine-market
While the market faces obstacles like the expensive cost of vaccinations hindering access in developing countries and vaccine hesitancy fueled by misinformation, the overall revenue growth is expected due to increased public awareness, government support for immunization programs, and the availability of combination vaccines.
- WHO recommends inclusion of tetanus toxoid vaccines in national immunization programs.
- FDA mandates safety standards for approval of tetanus toxoid vaccines in the United States.
- CDC’s Advisory Committee on Immunization Practices (ACIP) recommends tetanus toxoid vaccines for adults and adolescents.
- EMA sets standards for production, control, and distribution of tetanus toxoid vaccines in Europe.
Type Insights: In terms of revenue, the traditional tetanus toxoid vaccine segment dominated the global market in 2021. The market segments include conventional tetanus toxoid vaccine, tetanus toxoid with reduced diphtheria toxoid and acellular pertussis vaccine, tetanus toxoid and diphtheria toxoid vaccine, and tetanus toxoid with reduced diphtheria toxoid vaccine. The conventional tetanus toxoid vaccine, widely used for preventing tetanus infection, held the highest revenue share in 2021.
Explore Trending Reports:
Recycled Plastics Market-https://www.reportsanddata.com/report-detail/recycled-plastics-market
Propylene Oxide Market-https://www.reportsanddata.com/report-detail/propylene-oxide-market
Cellulose Ether Market-https://www.reportsanddata.com/report-detail/cellulose-ether-market
Logistics Automation Market-https://www.reportsanddata.com/report-detail/logistics-automation-market
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/992
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release